两种方法治疗2型糖尿病合并肺结核结果比较

Comparison of two treatment methods in patients of type 2 diabetes with tuberculosis

目的探讨罗格列酮联合胰岛素治疗2型糖尿病合并肺结核的疗效。方法对2型糖尿病合并肺结核66例患者在常规抗痨治疗的基础上，根据联合用药的不同，分为胰岛素组（DM＋INS）33例，联合治疗组（DM＋INS＋RSG）33例，动态观察血糖、肺结核病灶及痰菌培养的情况。结果DM＋INS＋RSG组不同时间痰菌阴转率均高于DM＋INS组（X^2=8．45，X^2=6．11，X^2=12．87，P〈0．05），两组病灶吸收和空洞闭合差异均有统计学意义（X^2=15．60，P〈0．05；X^2=5．00，P〈0．05），DM＋INS组治疗前后变化不明显；治疗后DM＋INS＋RSG组FPG、PPG和HbA1c较治疗前降低（P〈0．05～0．01）；与DM＋INS组间比较差异有统计学意义（P〈0．05-0．01）。结论对单用胰岛素治疗血糖控制欠佳的2型糖尿病患者可加用胰岛素增敏剂罗格列酮治疗，可使血糖和糖化血红蛋白得以良好的控制。

Objective To observe rosiglitazone（RSG） combined with insulin therapy in type 2 diabetes patients with tuberculosis. Methods 66 cases with type 2 diabetes and tuberculosis used the conventional antituberculosis treatment, divided into insulin group（ DM ＋ INS） 33 cases, the treatment group（ DM ＋ INS ＋ RSG） 33 with dynamic observation of blood glucose, and the lesions of tuberculosis in sputum culture. Results DM ＋ INS ＋ RSG group at the same time as the conversion rate is higher than DM ＋ INS group（X^2 = 8.45,X^2 = 6.11, X^2 = 12.87, P 〈 0 .05 ）, the lesions were closed and empty absorption were significantly different（X^2= 15.60, P 〈 0.05;X^2 = 5.00, P 〈 0.05 ） ,DM ＋ INS group before and after treatment did not change significantly. After treatment DM ＋ INS ＋ RSG group FPG,PPG and HbAlc levels lower than before treatment（P〈 0.05- 0.01 ） and DM ＋ INS group with significant differences（ P 〈 0.05- 0.01 ）. Conclusion The addition of rosiglitazone to insulin treatment results in significantly improvement in glycemic control in the type 2 diabetic patients.